Unomr is a deep-tech startup from ETH that is developing a patented analytical instrument to revolutionize medical research. By sequencing and measuring site-specific posttranslational modification like glycosylation of single proteins with unattainable accuracy and sensitivity, we give academic research as well as biotech and pharmaceutical companies new tools to study the effects of pharmaceutical products. With our serial nanopore technology, our customers can develop treatments for diseases that are currently incurable more quickly and efficiently. Our vision is to enable the analysis of rare proteins such as cancer biomarkers and protein sequencing with our team of experts who have years of experience in the development of biosensors.



For conference production and speaking opportunites:

Für die Produktion von Konferenzen und die Möglichkeit, Vorträge zu halten: 

For sponsorship and exhibition opportunities: